• Login
    View Item 
    •   Mak IR Home
    • College of Health Sciences (CHS)
    • School of Medicine (Sch. of Med.)
    • School of Medicine (Sch. of Med.) Collections
    • View Item
    •   Mak IR Home
    • College of Health Sciences (CHS)
    • School of Medicine (Sch. of Med.)
    • School of Medicine (Sch. of Med.) Collections
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Mannitol as adjunct therapy for childhood cerebral malaria in Uganda: a randomized clinical trial

    Thumbnail
    View/Open
    namutangula-chs-res.pdf (313.4Kb)
    Date
    2007-10-24
    Author
    Namutangula, Beatrice
    Ndeezi, Grace
    Byarugaba, Justus S. Justus S.
    Tumwine, James K
    Metadata
    Show full item record
    Abstract
    Background: Several reports have suggested that raised intracranial pressure (ICP) is a major contributor to death among children with cerebral malaria. Mannitol, an osmotic diuretic, effectively lowers ICP and is used to treat post-traumatic raised ICP. It is not clear whether intravenous mannitol given to children with cerebral malaria improves clinical outcome. The objective of this study was to determine the effect of mannitol as adjunct therapy on the clinical outcome of children with cerebral malaria. Methods: This randomized double-blind placebo controlled clinical trial was carried out at the Emergency Paediatric ward of Mulago Hospital, Uganda's national referral and teaching hospital. One hundred and fifty six children aged 6 to 60 months with cerebral malaria were randomized to either one dose of mannitol 1 g/kg or placebo, in addition to intravenous quinine. Main outcome measures included coma recovery time; time to sit unsupported, begin oral intake; duration of hospitalization; death and adverse effects. Results: Time to regain consciousness (p = 0.11), sit unsupported (p = 0.81), time to start oral intake (p = 0.13) and total coma duration (p = 0.07) were similar in both groups. There was no significant difference in the mortality between the placebo (13/80 or 16.3%) and mannitol (10/76 or 13.2%) groups: RR = 1.2 (CI 0.5–2.7). No adverse effects were observed after administration of mannitol. Conclusion: Mannitol had no significant impact on clinical outcome of cerebral malaria. It is difficult to recommend intravenous mannitol as adjunct therapy for childhood cerebral malaria.
    URI
    http://dx.doi.org/10.1186/1475-2875-6-138
    http://hdl.handle.net/10570/1072
    Collections
    • School of Medicine (Sch. of Med.) Collections

    DSpace 5.8 copyright © Makerere University 
    Contact Us | Send Feedback
    Theme by 
    Atmire NV
     

     

    Browse

    All of Mak IRCommunities & CollectionsTitlesAuthorsBy AdvisorBy Issue DateSubjectsBy TypeThis CollectionTitlesAuthorsBy AdvisorBy Issue DateSubjectsBy Type

    My Account

    LoginRegister

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    DSpace 5.8 copyright © Makerere University 
    Contact Us | Send Feedback
    Theme by 
    Atmire NV